These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37541423)

  • 1. Advancing novel therapies for neurodegeneration through an innovative model for industry-academia collaborations: A decade of the Eisai-UCL experience.
    Atkinson PJ; Swami M; Ridgway N; Roberts M; Kinghorn J; Warner TT; Staddon JM; Takle AK
    Drug Discov Today; 2023 Oct; 28(10):103732. PubMed ID: 37541423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Consideration on Industry-Academia Partnering in Drug Discovery Development: Based on a Questionnaire Survey of Pharmaceutical Companies and Academia].
    Iida K; Yano T; Ikemori M; Ishida T; Nishimura N
    Yakugaku Zasshi; 2021 Jun; 141(6):877-886. PubMed ID: 33642438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease.
    Jones R; Wilkinson D; Lopez OL; Cummings J; Waldemar G; Zhang R; Mackell J; Gauthier S
    Trials; 2011 Oct; 12():233. PubMed ID: 22029822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partnership between academia and industry for drug discovery in Alzheimer's disease.
    Ivinson AJ; Lane R; May PC; Hosford DA; Carrillo MC; Siemers ER
    Alzheimers Dement; 2008 Mar; 4(2):80-8. PubMed ID: 18631952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Consideration on Academia Environments for Creating Medical Innovation].
    Iida K; Ishida T; Nishimura N
    Yakugaku Zasshi; 2022 Jan; 142(1):75-84. PubMed ID: 34629350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development.
    Takebe T; Imai R; Ono S
    Clin Transl Sci; 2018 Nov; 11(6):597-606. PubMed ID: 29940695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging Industry-Academia Collaborations in Adaptive Biomedical Innovation.
    Stewart SR; Barone PW; Bellisario A; Cooney CL; Sharp PA; Sinskey AJ; Natesan S; Springs SL
    Clin Pharmacol Ther; 2016 Dec; 100(6):647-653. PubMed ID: 27617845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open for collaboration: an academic platform for drug discovery and development at SciLifeLab.
    Arvidsson PI; Sandberg K; Forsberg-Nilsson K
    Drug Discov Today; 2016 Oct; 21(10):1690-1698. PubMed ID: 27373760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accessing external innovation in drug discovery and development.
    Tufféry P
    Expert Opin Drug Discov; 2015 Jun; 10(6):579-89. PubMed ID: 25910932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of PET radiopharmaceuticals at the academia-industry interface.
    Bernard-Gauthier V; Collier TL; Liang SH; Vasdev N
    Drug Discov Today Technol; 2017 Nov; 25():19-26. PubMed ID: 29233263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Academic collaborations with industry: lessons for the future.
    Reddy SSK; Chao S
    J Investig Med; 2020 Dec; 68(8):1305-1308. PubMed ID: 33168581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective.
    Germann PG; Schuhmacher A; Harrison J; Law R; Haug K; Wong G
    Hum Genomics; 2013 Mar; 7(1):5. PubMed ID: 23496921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racing to define pharmaceutical R&D external innovation models.
    Wang L; Plump A; Ringel M
    Drug Discov Today; 2015 Mar; 20(3):361-70. PubMed ID: 25448753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders.
    Brady LS; Winsky L; Goodman W; Oliveri ME; Stover E
    Neuropsychopharmacology; 2009 Jan; 34(1):229-43. PubMed ID: 18800066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. University - industry collaborations: models, drivers and cultures.
    Ehrismann D; Patel D
    Swiss Med Wkly; 2015; 145():w14086. PubMed ID: 25658854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical industry, academia and patient advocacy organizations: what is the recipe for synergic (win-win-win) collaborations?
    Rose DM; Marshall R; Surber MW
    Respirology; 2015 Feb; 20(2):185-91. PubMed ID: 25580960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry.
    Litten RZ; Ryan M; Falk D; Fertig J
    Alcohol Clin Exp Res; 2014 May; 38(5):1196-9. PubMed ID: 24689461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of scientific collaboration in contemporary drug discovery and development: a detailed network analysis.
    Cheng F; Ma Y; Uzzi B; Loscalzo J
    BMC Biol; 2020 Oct; 18(1):138. PubMed ID: 33050894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public-Private Partnerships in Lead Discovery: Overview and Case Studies.
    Gottwald M; Becker A; Bahr I; Mueller-Fahrnow A
    Arch Pharm (Weinheim); 2016 Sep; 349(9):692-7. PubMed ID: 27335205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.